Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c
November 7, 2018 4:22 PM ESTArbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.49), $0.10 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $220 thousand.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
... More